Net profit of Ipca Laboratories rose 23.13% to Rs 282.57 crore in the quarter ended September 2025 as against Rs 229.48 crore during the previous quarter ended September 2024. Sales rose 8.56% to Rs 2556.50 crore in the quarter ended September 2025 as against Rs 2354.90 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2556.502354.90 9 OPM %21.3218.75 - PBDT553.17445.18 24 PBT449.84344.83 30 NP282.57229.48 23 Powered by Capital Market - Live News

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News

Ipca Laboratories has incorporated a wholly owned subsidiary by the name �Ipca Pharmaceuticals GmbH� in the Federal Republic of Germany, with an initial paid up capital of Euro � 25,000, inter-alia, to hold product registrations, participate in the institutional and other business and undertake distribution of generic formulations in the said country. Powered by Capital Market - Live News

Ipca Laboratories and BioSimilar Sciences PR LLC (BSS) today announced a definitive Technology Transfer and Joint Development Agreement that will shift late-stage development, clinical manufacture, and commercial supply of a next generation anti-cancer / anti-inflammatory monoclonal antibody biosimilar being developed by Ipca to BioSimilar Sciences PR LLC (BSS) 200,000 square feet sterile campus in Aguadilla, Puerto Rico.  Powered by Capital Market - Live News

Net profit of Ipca Laboratories rose 21.31% to Rs 233.21 crore in the quarter ended June 2025 as against Rs 192.24 crore during the previous quarter ended June 2024. Sales rose 10.33% to Rs 2308.85 crore in the quarter ended June 2025 as against Rs 2092.63 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales2308.852092.63 10 OPM %18.0418.77 - PBDT430.57389.28 11 PBT330.51290.39 14 NP233.21192.24 21 Powered by Capital Market - Live News